Cell-surface galactose-terminated glycoconjugates

Cell-surface galactose-terminated glycoconjugates are carbohydrate-protein or carbohydrate-lipid complexes where the terminal sugar residue is galactose or N-acetylgalactosamine (GalNAc). These structures are typically formed through the process of desialylation or specific biosynthetic pathways and serve as critical recognition motifs for various endogenous lectins, most notably the asialoglycoprotein receptor (ASGPR) found on hepatocytes (Stockert, 1995, Physiol Rev). In healthy physiology, they play a vital role in the clearance of aged or damaged glycoproteins from the blood circulation (Morell et al., 1971, J Biol Chem). In disease states, such as cancer, the expression of these glycoconjugates can be altered, leading to the exposure of neo-antigens like the Thomsen-Friedenreich antigen, which facilitates metastasis and immune evasion (Springer, 1984, Science). Modern pharmacology leverages these structures for highly specific drug delivery; for instance, GalNAc-conjugated small interfering RNAs (siRNAs) target these glycoconjugates (via the ASGPR) to achieve potent, liver-specific gene silencing (Nair et al., 2014, J Am Chem Soc). This targeting strategy has revolutionized the treatment of genetic disorders by improving the therapeutic index and reducing systemic toxicity of nucleic acid therapies.

Other names

Terminal galactose residuesAsialoglycansGalactose-terminated glycansGalNAc-terminated glycoconjugatesDesialylated glycoconjugates

Binding to the asialoglycoprotein receptor (ASGPR) to facilitate receptor-mediated endocytosis and intracellular delivery of therapeutic payloads to hepatocytes; or direct binding by antibodies/lectins for diagnostic or therapeutic purposes in cancer.